99 related articles for article (PubMed ID: 19602910)
1. The effect of intravitreal ranibizumab on the fellow untreated eye with subfoveal scarring due to exudative age-related macular degeneration.
Rouvas A; Liarakos VS; Theodossiadis P; Papathanassiou M; Petrou P; Ladas I; Vergados I
Ophthalmologica; 2009; 223(6):383-9. PubMed ID: 19602910
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
[TBL] [Abstract][Full Text] [Related]
3. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Kaiser PK; Blodi BA; Shapiro H; Acharya NR;
Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
[TBL] [Abstract][Full Text] [Related]
4. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
5. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
Wykrota H; Gierek-Lapińska A; Trzciakowski K; Gajdzik-Gajdecka U
Klin Oczna; 2007; 109(10-12):402-9. PubMed ID: 18488382
[TBL] [Abstract][Full Text] [Related]
6. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
7. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G
Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
[TBL] [Abstract][Full Text] [Related]
8. [Visual acuity and magnification requirement after ranibizumab in patients with wet age-related macular degeneration].
Kloos P; Bernasconi P; Estermann S; Bachmann B; Rutishauser Y; Thölen A
Klin Monbl Augenheilkd; 2008 May; 225(5):385-91. PubMed ID: 18454378
[TBL] [Abstract][Full Text] [Related]
9. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
Heier JS; Antoszyk AN; Pavan PR; Leff SR; Rosenfeld PJ; Ciulla TA; Dreyer RF; Gentile RC; Sy JP; Hantsbarger G; Shams N
Ophthalmology; 2006 Apr; 113(4):633.e1-4. PubMed ID: 16483659
[TBL] [Abstract][Full Text] [Related]
10. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
11. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Rosenfeld PJ; Heier JS; Hantsbarger G; Shams N
Ophthalmology; 2006 Apr; 113(4):623.e1. PubMed ID: 16581423
[TBL] [Abstract][Full Text] [Related]
12. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
[TBL] [Abstract][Full Text] [Related]
13. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
Brown MM; Brown GC; Brown HC; Peet J
Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
[TBL] [Abstract][Full Text] [Related]
14. Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide.
Jonas JB; Spandau UH; Harder B; Vossmerbaeumer U; Kamppeter BA
Am J Ophthalmol; 2005 Jun; 139(6):1073-9. PubMed ID: 15953439
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic approaches to age-related macular degeneration today.
Bressler NM
Ophthalmology; 2009 Oct; 116(10 Suppl):S15-23. PubMed ID: 19800535
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
Regillo CD; Brown DM; Abraham P; Yue H; Ianchulev T; Schneider S; Shams N
Am J Ophthalmol; 2008 Feb; 145(2):239-248. PubMed ID: 18222192
[TBL] [Abstract][Full Text] [Related]
17. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab.
Parravano M; Oddone F; Tedeschi M; Schiano Lomoriello D; Chiaravalloti A; Ripandelli G; Varano M
Retina; 2009 Mar; 29(3):329-34. PubMed ID: 19092732
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
[TBL] [Abstract][Full Text] [Related]
19. [Combination of Intravitreal rTPA, gas and ranibizumab for extensive subfoveal haemorrhages secondary to neovascular age-related macular degeneration].
Matt G; Sacu S; Stifter E; Prünte C; Schmidt-Erfurth U
Klin Monbl Augenheilkd; 2010 Mar; 227(3):221-5. PubMed ID: 20234987
[TBL] [Abstract][Full Text] [Related]
20. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Boyer DS; Antoszyk AN; Awh CC; Bhisitkul RB; Shapiro H; Acharya NR;
Ophthalmology; 2007 Feb; 114(2):246-52. PubMed ID: 17270674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
